HealthCare Global Enterprises

What HealthCare Global Enterprises does

HealthCare Global Enterprises Limited (HCG), founded in 1989 by Dr. B.S. Ajaikumar, operates India's largest dedicated cancer care hospital network, with 25 hospitals across 19 cities in India and Africa plus a current capacity of approximately 2,500 beds. The company provides comprehensive oncology services spanning diagnosis, surgical oncology, radiation therapy (including Karnataka's first Elekta Unity MR-Linac at its Hebbal facility), chemotherapy, robotic-assisted surgery (five robotic theatres), and precision medicine via molecular diagnostics and genomics. HCG is differentiated from Indian multispecialty hospital chains (Apollo, Max, Fortis) by its exclusive focus on oncology and a patient-for-life model.

HCG generates revenue primarily through its hospital services across India, supplemented by international medical tourism (notably from West Asian markets) and an East Africa joint venture (Healthcare Global (Africa)) with CDC. FY26 consolidated revenue was Rs 2,545 crore, up 15% year-on-year, with adjusted EBITDA of Rs 471 crore at 18.5% margins (improved from 17.8% in FY25). Management targets 22-25% EBITDA margins medium-term via 100bps annual expansion. Pricing is quote-based per treatment, varying by cancer type, duration, and room category.

The company is publicly listed on Indian stock exchanges with KKR holding an approximately 54% controlling stake acquired in 2025 for Rs 3,466 crore (~$400 million), the largest PE investment in Indian healthcare. HCG raised an additional Rs 425 crore via rights issue in February 2026 for robotics, diagnostics, and oncology infrastructure. The company operates a 5,001-10,000 employee base, is pursuing a 1,000-bed expansion over five years across tier-2 cities, and is reported as a potential bidder for Siemens Healthineers' American Oncology Institute. Recent geopolitical tensions have caused a 60-70% decline in West Asian patient volumes (March-May 2026), representing a measurable near-term headwind to the international medical tourism revenue stream.

Name

HealthCare Global Enterprises

Legal name

HealthCare Global Enterprises Limited

Website

https://hcgel.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

HealthCare Global Enterprises (HCG) operates India's largest dedicated cancer care network, with 25 hospitals across 19 cities in India and Africa, serving cancer patients through oncology diagnostics, radiation therapy, robotic surgery, and precision medicine.

Ownership category

akta.pro rank

Product category

Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Specialty (except Psychiatric and Substance Abuse) Hospitals (62231)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Medical Oncology (HLAKAFAB)

Keywords

• Oncology hospital services
• Cancer treatment network
• Radiation therapy services
• Precision medicine oncology
• Robotic cancer surgery

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Hospital Services Revenue: HCG generates primary revenue through operating its network of 25 cancer hospitals across India and Africa, providing diagnostic services, treatment, and care to cancer patients. FY26 consolidated revenue was Rs 2,545 crore, up 15% year-on-year.
2. Medical Tourism: International patients, particularly from West Asian countries, contribute to revenue. The company reported a 60-70% decline in patient volumes from West Asia between March and May 2026 due to geopolitical tensions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

HealthCare Global Enterprises (HCG) operates a network of 25 dedicated cancer care hospitals across 19 cities in India and Africa, delivering oncology diagnosis, treatment, and survivorship services. Core offerings include surgical oncology, radiation therapy, medical oncology, and chemotherapy, supported by advanced technologies such as Karnataka's first Elekta Unity MR-Linac, robotic-assisted surgery, and precision medicine including molecular diagnostics and genomics. The network serves both domestic Indian patients and international medical tourists, with tier-2 city expansion and an Africa joint venture scaling geographic reach.

Product overview

HealthCare Global Enterprises (HCG) operates as India's largest dedicated cancer care hospital network with a platform-plus-services architecture. The core offering is the HCG Cancer Care Network comprising 25 hospitals across 19 cities plus international operations in Kenya. Additional modules include precision medicine, molecular diagnostics, genomics, and robotic-assisted surgery capabilities. The network provides comprehensive oncology services from diagnosis through treatment, with recent expansion into advanced technologies including Karnataka's first Elekta Unity MR-Linac for precision radiation therapy. HCG also operates a joint venture in Africa through Healthcare Global (Africa) for affordable cancer treatment.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Revenue growth of 15% year-on-year to Rs 2,545 crore in FY26
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• CDC (CDC Group)coreStrategic or Co-development PartnerHealthcare Global (Africa) is a joint venture between CDC and Healthcare Global Enterprises, aimed at providing affordable cancer treatment in Africa. The project involves establishing centers of excellence, deploying advanced technology, and improving early detection and treatment options.
• SalarySeminorStrategic or Co-development PartnerSalarySe partnered with HCG to provide AI-powered financial health solutions to HCG employees. Queen Maxima of the Netherlands visited HCG's Colaba Hospital to observe how UPI-powered innovations and AI-driven financial health solutions improve outcomes for salaried workers.
• Siemens HealthineersminorStrategic or Co-development PartnerHCG is reportedly among potential bidders for Siemens Healthineers' American Oncology Institute (AOI), which operates 16 hospitals across India and one in Sri Lanka. The potential acquisition is valued at Rs 1,500-2,000 crore.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Fortis Healthcare: Fortis runs a nationwide multi-specialty hospital network that includes oncology services, giving it overlapping capabilities with HCG in cancer diagnosis, chemotherapy, and radiation therapy. Its broader portfolio and larger balance sheet position it as a broad incumbent competing for the same tertiary oncology referrals.
• Medanta - The Medicity: Medanta is a leading multi-specialty tertiary care hospital group in India offering comprehensive cancer care including surgical, medical and radiation oncology. Its institutional reputation and multi-specialty positioning place it as a broad incumbent competing with HCG for complex cancer cases across North India.
• Manipal Hospitals: Manipal Hospitals operates one of India's largest multi-specialty hospital chains and has expanded its oncology footprint, including academic and tertiary cancer services. It competes with HCG for oncology patients while also serving broader specialties, placing it in the broad incumbent peer set.
• Apollo Hospitals Enterprise: Apollo is India's largest hospital chain with a strong oncology program across its multi-specialty network, including advanced radiation and surgical oncology. While not oncology-exclusive, Apollo's scale, brand, and capital access make it HCG's most significant broad competitor and a key benchmark for valuation (50-80x trailing cash flows vs HCG's ~30x).
• Max Healthcare Institute: Max Healthcare operates a North India-centric hospital network with a growing oncology program spanning medical, surgical, and radiation oncology. Like Apollo and Fortis, it competes for tertiary cancer cases while offering broader specialties, serving as a broad incumbent benchmark for HCG.

Direct peers

• American Oncology Institute (AOI) / Siemens Healthineers: AOI operates 16 dedicated cancer hospitals across India and one in Sri Lanka, making it one of HCG's closest direct comparables in specialty oncology. HCG is reportedly among potential bidders for AOI, underlining the head-to-head competition for inpatient oncology share and clinical talent in India.
• Cytecare Cancer Hospitals: Cytecare is a Bengaluru-based dedicated cancer hospital network focused on organ-specific oncology, mirroring HCG's specialty-only model. With concentrated cancer-only operations in India, it is one of HCG's most direct specialty oncology peers competing for the same patient pool and clinical talent.

Regional players

• Tata Memorial Hospital: Tata Memorial is a premier government-funded cancer hospital in Mumbai that serves as a national referral center for oncology in India. While it operates in the same disease specialty and geography, its public/government funding model and lack of commercial expansion distinguish it from HCG's private specialty network.
• Basavatarakam Indo-American Cancer Hospital & Research Institute: Basavatarakam is a large dedicated cancer hospital in Hyderabad offering comprehensive oncology services to patients across South India. Its specialty-only focus makes it directly comparable to HCG's cancer-only model, though it is regionally concentrated rather than nationally scaled.

Others

• City of Hope: City of Hope is a US-based specialty cancer research and treatment system operating dedicated oncology hospitals and a National Cancer Institute-designated comprehensive cancer center. While geographically separate, it is thematically comparable as a specialty oncology hospital operator and reference point for HCG's clinical and research ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/HealthCare-Global-Enterprises-Limited-1657553981163476
• LinkedInlinkedin.com/company/healthcare-global-enterprises-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HealthCare Global Enterprises